These foods are the heaviest hitters. While GLP-1 drugs have transformed how many people think about weight loss, the ...

A newly studied hormone is revealing an unexpected connection between metabolism and the brain. A hormone that can reverse ...

The global rise in the prevalence of obesity highlights the need for accessible and effective solutions for obesity ...

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has ...

Study of almost 28,000 people also identifies genetic variants that raise the risk of gastrointestinal side effects from ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...

Among medically eligible respondents, nearly three-fourths (74%) identified GLP-1 coverage as a top-tier health priority. One ...

Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early ...

The daily pill, called Foundayo, could make it easier for more people to lose weight.

The Endocrine Society has concerns of possible delays in care and other problematic areas of The Lancet Commission’s proposed new obesity framework; a Commission author cites ‘conceptual confusions.’ ...